Hepatitis Monthly

Published by: Kowsar

Prevalence of National Responsiveness to HBV Vaccine After 22 Years of Iranian Expanded Program on Immunization (EPI): A Systematic Review and Meta-Analysis Study

Reza Rezaee 1 , Bahman Aghcheli 2 , Vahdat Poortahmasebi 2 , Mostafa Qorbani 3 , 4 , Seyed Moayed Alavian 5 and Seyed Mohammad Jazayeri 2 , *
Authors Information
1 Ministry of Health and Medical Education, Deputy of Curative Affairs, Budget Administration, Tehran, IR Iran
2 Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Community Medicine, Alborz University of Medical Sciences, Karaj, IR Iran
4 Non-Communicable Disease Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, IR Iran
5 Middle East Liver Diseases Center (MELD Center), Tehran, IR Iran
Article information
  • Hepatitis Monthly: May 01, 2015, 15 (5); e23618
  • Published Online: April 25, 2015
  • Article Type: Review Article
  • Received: September 14, 2014
  • Revised: December 16, 2014
  • Accepted: March 29, 2015
  • DOI: 10.5812/hepatmon.15(4)2015.23618

To Cite: Rezaee R, Aghcheli B, Poortahmasebi V, Qorbani M, Alavian S M, et al. Prevalence of National Responsiveness to HBV Vaccine After 22 Years of Iranian Expanded Program on Immunization (EPI): A Systematic Review and Meta-Analysis Study, Hepat Mon. 2015 ; 15(5):e23618. doi: 10.5812/hepatmon.15(4)2015.23618.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Discussion
Acknowledgements
Footnote
References
  • 1. Ding X, Yang Y, Han B, Du C, Xu N, Huang H, et al. Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation. PLoS One. 2014; 9(5)[DOI][PubMed]
  • 2. WHO . Expanded programme on immunisation Report of 14th Global Advisory Group. 1991;
  • 3. Thomas HC., Lok A., Locarnini E., Zuckerman A.. Variants of Hepatitis B Surface Antigen (HBsAg) 2014; : 107-26
  • 4. Zuckerman JN. Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production. J Med Virol. 1996; 50(4): 283-8[DOI][PubMed]
  • 5. Milich DR, Leroux-Roels GG. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev. 2003; 2(5): 248-57[PubMed]
  • 6. Jilg W, Schmidt M, Deinhardt F. Four-year experience with a recombinant hepatitis B vaccine. Infection. 1989; 17(2): 70-6[PubMed]
  • 7. Chiara F, Bartolucci GB, Cattai M, Piazza A, Nicolli A, Buja A, et al. Hepatitis B vaccination of adolescents: significance of non-protective antibodies. Vaccine. 2013; 32(1): 62-8[DOI][PubMed]
  • 8. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet. 2000; 355(9203): 561-5[PubMed]
  • 9. Saffar MJ, Rezai MS. Long-term antibody response and immunologic memory in children immunized with hepatitis B vaccine at birth. Indian Pediatr. 2004; 41(12): 1232-7[PubMed]
  • 10. Behjati Ardakani M,, Mir Hosseini NA,, Ayatollahi J. [Survey of hepatitis B surface antigen titers in vaccinated 8 years old school children of Yazd] Shahid Sadoughi Uni Med Sci And Health svc J 2002; 10(3): 3-7
  • 11. Taghavi Ardakani A, Soltani B, Sharif MR, Moosavi GA, Khademian M. [Evaluation of serum hepatitis B antibody level in vaccinated children after 14 years in Kashan, Iran.] J Gorgan Univ Med Sci. 2012; 14(3): 104-8
  • 12. Hadi N, Hadi N. Assessment of anti-HBs antigen in 6- to 9-year-old children routinely vaccinated via vaccination program in Iran. Med Princ Pract. 2007; 16(4): 306-9[DOI][PubMed]
  • 13. Jafarzadeh A, Montazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub Med Coll Abbottabad. 2006; 18(4): 4-9[PubMed]
  • 14. Afsharian M, Ghaderi M, Vaziri S, Leghaei Z, Ghadiri K, Janbaksh A, et al. [Seroconversion rates after hepatitis-B vaccination in children.] J Kermanshah Univ Med Sci. 2012; 15(6): 481-4
  • 15. Yazdanpanah B, Safari M, Yazdanpanah S. Persistence of HBV Vaccine's Protection and Response to Hepatitis B Booster Immunization in 5- to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran. Hepat Mon. 2010; 10(1): 17-21[PubMed]
  • 16. Mahyar A.. [Survey of Antibody Titers against Recombinant Hepatitis B Vaccination in 6 Years old Children]. 3. 2007; 16(61): 39-43
  • 17. Rafizade B, Kazemi AN, Amir Moghadami HR, Moosavi Nasab N. [Survey of Anti-HBs Serum Level in Vaccinated 7-9 Year-old Children in Zanjan City 2004]. ZUMS J. 2004; 12(47): 49-55
  • 18. Mostafavi Zadeh K, Salehi H, Imani R, Haghayegh MR. Antibody level against of hepatitis B surface antigen after vaccination in children aged 5 to 6 years old after the newly school in the city shahrekord. Res Med Sci. 2001; 6(3): 194-194
  • 19. Esmaili M, Seyedkolal F. [Evaluation of anti HBS levels in vaccinated children against Hepatitis B, Amirkola Hospital, Babol] KAUMS J ( FEYZ ) 2003; 6(4): 45-49
  • 20. Shamsizadeh A, Makvandi M, Shoshtari G. Prevalence of anti hepatitis B surface antibody among children in Ahvaz, Iran, five years after vaccination. Jundishapur J Microbiol. 2011; 4(1)
  • 21. Hosseini SM, Ranjbar R, Abolghasemi H, Turkaman M. Evaluation of the Level of HBV Antibody Titer after HBV Vaccination among Children in Tehran, Iran. Hepat Mon. 2009; 9(2): 150-3
  • 22. Salehi H, Farajzadegan Z. Antibody titer in Iranian children 6 years after hepatitis B vaccine administration. Vaccine. 2007; 25(17): 3511-4[DOI][PubMed]
  • 23. Ahmadi M, Moosavi SM, Jahanfar F. [Comparison of antibody level in post hepatitis B vaccination in children with 12-15 and 21-24 months age]. J Gorgan Univ Med Sci. 2012; 14(2): 59-65
  • 24. Kazemi A, Koosha A, Rafizadeh B, Mousavinasab N, Mahram M. Serum level of anti-hepatitis B surface antigen 6-8 years after hepatitis B vaccination at birth. East Mediterr Health J. 2008; 14(4): 960-5[PubMed]
  • 25. Azarkar Z. [Efficacy of hepatitis B vaccine in children from 12 to 16 months in Mashad health centers]. J Qazvin Univ of Med Sci. 2004; 7(5): 38-41
  • 26. Dahifar H. Immunogenicity of Cuban hepatitis B vaccine in Iranian children. Arch Iranian Med. 2004; 7(2): 89-92
  • 27. Jafarzadeh A, Khoshnoodi J, Ghorbani S, Hazrati SM, Mazaheri BF, Shokri F. Differential Immunogenicity of A Recombinant Hepatitis B Vaccine in Iranian Neonates: Influence of Ethnicity and Environmental Factors. Int J Infect. 2004; 1(2): 98
  • 28. Fatolah Poor A, Hematpoor S, Ghaderi E. Effect of hepatitis B vaccination in children vaccinated between 12 and 24 months old city of Sanandaj. Journal of Infectious Diseases. 2008; 41(1): 65-70
  • 29. Salehi M, Sanei Moghadam E, Khosravi S. [Evaluation of immune response of Hepatitis B vaccination in Zahedan infants.] Zahedan J Res Med Sci. 2002; 4(3): 155-8
  • 30. Moradi A. [The response rate to hepatitis B vaccination in children younger than one year of Gorgan.] J Gorgan Univ Med Sci. 2008; 10(2): 50-5
  • 31. Zamani A, Shajari H, Sedighy I. Study On The Ef Ficacy Of Recombinant Hepatitis B Vaccine In Iranian Infants. Med J Islamic Repub Iran. 2001; 14(4): 347-9
  • 32. Shokri F, Jafarzadeh A. High seroprotection rate induced by low doses of a recombinant hepatitis B vaccine in healthy Iranian neonates. Vaccine. 2001; 19(31): 4544-8[PubMed]
  • 33. Rostami N, Ghaffari V, Samaie H. Comparison of Immune Response to Hepatitis B Vaccine Between Term and Preterm Infants at Birth. Arch Clin Infect Dis. 2006; 7(1): 11-4
  • 34. Rezaei M, Nooripoor S, Ghorbani R, Ramezan Shams F, Mamishi S, Mahmoudi S. Seroprotection after hepatitis B vaccination in children aged 1 to 15 years in central province of Iran, Semnan. J prev med hyg. 2014; 55(1): 1-3
  • 35. Elian F, Shubair M. Evaluation of the efficacy of Hepatitis B vaccine in different age groups of immunized children in Gaza strip. Islamic Univ J. 2006; 14(1): 91-103
  • 36. Livramento A, Cordova CM, Scaraveli NG, Tonial GC, Spada C, Treitinger A. Anti-HBs levels among children and adolescents with complete immunization schedule against hepatitis B virus. A cross-sectional study in Blumenau, State of Santa Catarina, Brazil, 2007-2008. Rev Soc Bras Med Trop. 2011; 44(4): 412-5[PubMed]
  • 37. Madour A, Alkout A, Vanin S. First evaluation of the serum level of anti-hepatitis B surface antigen after vaccination in Libya. East Mediterr Health J. 2013; 19(12): 990-4[PubMed]
  • 38. Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005; 366(9494): 1379-84[DOI][PubMed]
  • 39. Dong Y, Liu SL, Zhai XJ, Zhu FC, Pan H, Yu JX, et al. A serological and molecular survey of hepatitis B in children 15 years after inception of the national hepatitis B vaccination program in eastern China. J Med Virol. 2009; 81(9): 1517-24[DOI][PubMed]
  • 40. Sallam TA, Alghshm HM, Ablohom AA, Alarosi MS, Almotawakel RE, Farea NH, et al. Immune response to Hepatitis B vaccine among children in Yemen. Saudi Med J. 2005; 26(2): 281-4[PubMed]
  • 41. Belloni C, Chirico G, Pistorio A, Orsolini P, Tinelli C, Rondini G. Immunogenicity of hepatitis B vaccine in term and preterm infants. Acta Paediatr. 1998; 87(3): 336-8[PubMed]
  • 42. Hwang LY, Beasley RP, Stevens CE, Szmuness W. Immunogenicity of HBV vaccine in healthy Chinese children. Vaccine. 1983; 1(1): 10-2[PubMed]
  • 43. Chongsrisawat V, Yoocharoen P, Theamboonlers A, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S, et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health. 2006; 11(10): 1496-502[DOI][PubMed]
  • 44. Sadeck LS, Ramos JL. [Immune response of preterm infants to hepatitis B vaccine administered within 24 hours after birth]. J Pediatr (Rio J). 2004; 80(2): 113-8[PubMed]
  • 45. Aypak C, Yuce A, Yikilkan H, Gorpelioglu S. Persistence of protection of hepatitis B vaccine and response to booster immunization in 2- to 12-year-old children. Eur J Pediatr. 2012; 171(12): 1761-6[DOI][PubMed]
  • 46. Liao SS, Li RC, Li H, Yang JY, Zeng XJ, Gong J, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine. 1999; 17(20-21): 2661-6[PubMed]
  • 47. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005; 142(5): 333-41[PubMed]
  • 48. Hofmann F, Kralj N. Criteria for successful hepatitis B vaccination in adults: results of a case study. Infection. 2009; 37(3): 266-9[DOI][PubMed]
  • 49. Boot HJ, van der Waaij LA, Schirm J, Kallenberg CG, van Steenbergen J, Wolters B. Acute hepatitis B in a healthcare worker: a case report of genuine vaccination failure. J Hepatol. 2009; 50(2): 426-31[DOI][PubMed]
  • 50. Rosenberg C, Bovin NV, Bram LV, Flyvbjerg E, Erlandsen M, Vorup-Jensen T, et al. Age is an important determinant in humoral and T cell responses to immunization with hepatitis B surface antigen. Hum Vaccin Immunother. 2013; 9(7): 1466-76[DOI][PubMed]
  • 51. do Livramento A, Schultz J, Batista KZ, Treitinger A, de Cordova CM, Spada C. Immune memory response induced in vitro by recombinant hepatitis B surface antigen challenge 13-18 years after primary vaccination. J Med Virol. 2014; 86(10): 1700-4[DOI][PubMed]
  • 52. Karimzadeh H, Pakzad SR, Mahmoudi M, Ajdary S, Norouzi M, Akbari M. [Set up of analytical methods for evaluation of specifications of recombinant Hepatitis-B vaccine]. Tehran Unive Med Sci. 2009; 67(3)
  • 53. Karimzadeh H, Ajdary S, Jazayeri SM, Pakzad SR. Validation of an in-vitro method for Hepatitis B vaccine potency assay: specification setting. Panminerva Med. 2010; 52(3): 177-82[PubMed]
  • 54. Davaalkham D, Ojima T, Wiersma S, Lkhagvasuren T, Nymadawa P, Uehara R, et al. Administration of hepatitis B vaccine in winter as a significant predictor of the poor effectiveness of vaccination in rural Mongolia: evidence from a nationwide survey. J Epidemiol Community Health. 2007; 61(7): 578-84[DOI][PubMed]
  • 55. de la Hoz F, Perez L, de Neira M, Hall AJ. Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness. Int J Infect Dis. 2008; 12(2): 183-9[DOI][PubMed]
  • 56. De La Hoz F, Hall AJ. Hepatitis B Vaccination In The Colombian Amazon Effectiveness And Factors Influencing Vaccination Coverage. 2002;
  • 57. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis. 2009; 200(1): 39-47[DOI][PubMed]
  • 58. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007; 16(4): 403-6[PubMed]
  • 59. Alavian SM, Hajarizadeh B, -Asl MA, Kabir A, Lankarani KB. Hepatitis B Virus Infection in Iran: A Systematic Review. Hepat Mon. 2008; 8(4): 281-94
  • 60. Delavari M, Shahabinejhad N, Renzaho A, Zahedi M, Owhadi AR. Frequency of Anti-HBc & HBV DNA detection in blood donors of Kerman province, Iran. J Blood Disord Transfus. 2011; 2(1): 1-4
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments